Objective: To evaluate the literature and educate the pharmacy community about the different treatment options for vulvodynia. Data Sources: Searches were performed through MEDLINE (1946-May 2018) using OVID and EBSCOhost, and Excerpta Medica (1974-May 2018 using EMBASE. Search terms included vulvar vestibulitis syndrome, vestibulodynia, vulvodynia, vulvar pain, provoked vulvar vestibulitis, and vulvodynia treatment. References of all relevant articles were then used to find additional applicable articles. Study Selection and Data Extraction: This review includes articles in the English language and human trial literature. Twenty-five trials explored the use of oral and topical medications in the treatment of vulvodynia. Data Synthesis: Vulvodynia is a poorly understood disease with an unknown etiology. Oral tricyclic antidepressants and gabapentin continue to be the most commonly used treatments for vulvodynia pain. This is due to their ease of use and patient preference. Topical treatments that have efficacy data are amitriptyline, gabapentin, lidocaine, baclofen, and hormones. This route of administration avoids systemic adverse effects and interpatient variability that accompanies oral administration. Alternative therapies more commonly used include physiotherapy, psychotherapy, and surgery. Treatment length may vary due to dose titrations and potential changes in medication therapy. Conclusions: Several medication and alternative therapies may be effective in treating vulvodynia. Current studies used wide dosing ranges, making it difficult to standardize therapy. No consistent method of assessing pain was used between studies, as well as a limited number being randomized and placebo controlled. Additional research is needed to increase knowledge and further develop vulvodynia treatments.
Introduction
Vulvodynia was defined in 2003 as "vulvar discomfort, most often described as burning pain without relevant visible findings or a specific, clinically identifiable, neurologic disorder" by the International Society for the Study of Vulvovaginal Disease (ISSVD). 1 The pain can be described as burning, itching, stinging, rawness, or irritation that may be localized to one area or generalized to the entire vulva. It could be triggered by direct touch (inserting a tampon or sexual intercourse), indirectly by walking, or even without provocation. 2 It was estimated in 2012 that vulvodynia affects about 8% of women in the United States. 3 That estimation increased to 16% in 2014. 4 However, due to the negative psychological and sexual impact of vulvodynia and the number of patients who do not seek treatment, this number is probably underreported. Historically, lack of evidence during physical examination has led some practitioners to believe this was strictly a psychological problem. 5 However, vulvodynia has been shown as a multifactorial disorder with no one proven etiology. Some of the suggested etiologies or associated factors have been genetics, inflammation, frequent yeast infections, neuropathic pain, pelvic floor hypertonic dysfunctions, pelvic organ prolapse, hormone imbalances/hormonal contraceptives, high urine oxalates, and psychological disorders. 1, [5] [6] [7] Many terms have been used to describe vulvar pain. Initially, it was identified as psychosomatic vulvovaginitis, pudendagra or burning vulva syndrome, focal vulvitis, vulvar vestibulitis syndrome, and vestibulodynia. Due to the wide variety of terms, the ISSVD met in 1999, 2001 , and 2003 to continue modifications in terminology. The panel initially released terms referring to the pain as either generalized or localized vulvar dysesthesia, which was later expanded to include either provoked or spontaneous vulvar dysesthesia. 1 In 2015, another panel of specialized professional organizations was assembled to update the definition of vulvodynia to match ongoing research. The panel included representatives from the ISSVD, the International Society for the Study of Women's Sexual Health, and the International Pelvic Pain Society. The updated definition identifies vulvar pain related to a specific disorder or vulvodynia, the latter having potential descriptors used to describe the quality of pain (Table 1) . Vulvodynia is a diagnosis of exclusion, which requires ruling out other potential sources of pain, and the pain must be at least 3 months in duration. 1 Due to the complexity and increasing prevalence of the disease, a thorough look at the available research is warranted. The objective of this article is to inform the pharmacy community about vulvodynia treatments and to suggest individualized treatment options to patients and healthcare providers.
Data Sources
The literature review included an English language and human trial literature search through MEDLINE (1946-May 2018) using OVID and EBSCOhost, and Excerpta Medica (1974-May 2018) using EMBASE. Search terms included vulvar vestibulitis syndrome, vestibulodynia, vulvodynia, vulvar pain, provoked vulvar vestibulitis, and vulvodynia treatment. References of all relevant articles were then used to find additional applicable articles. This search yielded 4 randomized-controlled trials, 11 prospective nonrandomized trials, 7 retrospective reviews, and 3 case reports over oral and/or topical therapies, which are the focus of this article. Additional studies and review articles over injectable and alternative therapies were also included for completeness.
Treatment Considerations
Since vulvodynia was initially assumed to be a psychological problem, early treatment focused on oral antidepressant therapy. As research grew, neurological modes of treatment were explored to include topical therapies and combinations of both oral and topical treatments. While oral and topical therapies remain the predominant strategies for treatment, there have been several alternative and nonpharmacological therapies that have also been explored. Patients should expect to take several months to achieve maximal symptom reduction due to dose titrations and potential changes in medication therapy. Since women of childbearing age can be affected by this condition, medication pregnancy risk factor should be considered when selecting therapy.
Oral Therapies
Oral medications have historically been a favored treatment option. In a survey of women's preferences when dealing with intravaginal medications, 72.1% of patients with prior experience using vaginal products preferred the oral route over the vaginal route. This percentage increased to 83.2% in women without experience using vaginal products. Their reasoning for preferring the oral route was due to comfort (98.0%), safety (9.0%), and efficacy (6.9%). 8 First-line therapy for vulvodynia matches closely with neuropathic pain strategies, which includes use of certain antidepressants and anticonvulsants.
5 Table 2 provides a condensed view of the 13 oral therapy studies that tested systemic treatment options.
Antidepressants
Tricyclic antidepressants (TCAs) have been the focus for both oral and topical therapies due to their dual effects in treating depression and neuropathic pain. Amitriptyline has thus far been the most researched TCA and is widely used by healthcare professionals. However, the wide range of amitriptyline dosing (10 mg to 225 mg taken by mouth daily) and lack of a consistent method of assessing pain further complicate the ability to extrapolate useful efficacy data from studies. [9] [10] [11] [12] Additionally, TCA use is associated with adverse effects such as weight gain, fatigue, tachycardia, and seizures. 9, 12, 13 The only other TCA researched in vulvodynia is desipramine. The singular placebo-controlled trial that tested desipramine both alone and in combination with topical lidocaine 5% demonstrated improvement in pain scores in both the treatment and placebo arms, but found no significant difference between these groups. 13 Newer antidepressants have also been utilized due to their more favorable adverse effect profile compared with TCAs and their effectiveness in the management of other pain syndromes, such as fibromyalgia. One case report on the use of a low-dose serotonin-norepinephrine reuptake inhibitor (SNRI), venlafaxine 75 mg daily, showed that the patient was able to achieve complete remission of symptoms. 14 In another SNRI study, milnacipran (titrated up to 200 mg daily) also showed some lowering of pain scores when studied in provoked vestibulodynia. Although these results were statistically significant, the trial recognized that women with a sexually satisfying relationship at baseline were 3 times more likely to show improvement compared with those who did not have a sexually satisfying relationship. The major adverse effects experienced with milnacipran in this study were nausea, headaches, hot flushes, and dizziness. 15 Selective serotonin reuptake inhibitors (SSRIs) have not been studied individually but rather in a combination regimen or after the failure of a TCA. These include escitalopram, paroxetine, and citalopram. Oral escitalopram, amitriptyline, and perphenazine were researched in vulvodynia patients in one study. Although 52.7% of patients in the treatment arm reported complete remission, the study lacked a placebo. 16 Reed et al 10 conducted a study where participants were initiated on a TCA, unless contraindicated, and progressed to either another antidepressant (paroxetine or another unspecified SSRI) or an anticonvulsant (gabapentin). While the TCA pain reduction scores were statistically significant, the SSRI and gabapentin scores were not statistically significant. In another study, citalopram was also used in conjunction with pregabalin, but citalopram was not the focus of that study since the patient had been taking it at baseline.
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Anticonvulsants
When neuropathic pain is suspected, the practitioner may consider starting an anticonvulsant as either monotherapy or in combination with an antidepressant. Thus far, studies have been limited to gabapentin, pregabalin, lamotrigine, and carbamazepine.
Although initially marketed as an anticonvulsant, gabapentin has shown efficacy in treating neuropathic pain. For this reason, investigators have studied its use in vulvodynia both topically and orally. In 3 out of 4 trials using oral gabapentin, the dosage was titrated up gradually based on tolerability and efficacy. Therefore, there are wide-ranging dosages (100 mg to 3000 mg orally each day in divided doses), making it difficult to extrapolate specific dose-response relationships. These 3 studies resulted in at least a partial response to therapy of roughly 60% to 80% of patients. [18] [19] [20] In contrast, the fourth study used a standard dose of 300 mg twice daily for all patients versus the wide-ranging dosages seen in the other 3 studies. Pain relief between 80% and 100% was reported for 25% of the patients, while 50% of the patients reported 0% to 19% pain relief. The study was limited to just 8 patients who started gabapentin only after failing amitriptyline therapy. 12 Potential adverse effects from gabapentin therapy reported in these studies included fatigue, dizziness, and headaches. 12, [18] [19] [20] Pregabalin studies have been limited to a case report and a study where it was initiated only if there was a contraindication or adverse effect to amitriptyline. In these trials, patients subjectively stated the percentage of pain relief that treatment had accomplished. In the case study, 17 the patient stated that she had 80% relief of symptoms while taking oral pregabalin 250 mg nightly and also taking oral citalopram 20 mg daily, while the retrospective study 12 showed that 42% of patients had between 80% and 100% relief of symptoms after progressing from TCA therapy failure. Adverse effects from pregabalin included abdominal discomfort, drowsiness, dry mouth, and headache. 12 Although pregabalin shows some efficacy, there were wide dosing ranges and potential confounders with medications used concomitantly.
The only study involving lamotrigine was an open-label pilot study including patients proven to be refractory to other medications that included TCAs, opioids, and nonsteroidal anti-inflammatory drugs. If the patient had been taking one of these medications for longer than 4 weeks, she was allowed to continue taking that medication after starting lamotrigine. These concomitantly used medications potentially confounded the results of this study. Although vulvodynia patients taking lamotrigine showed improvement in pain and mood scores, the study failed to meet power and lacked a control arm. Reported adverse effects included minor rash, headache, and fatigue. 21 Carbamazepine has similarly been limited to a singular study. As seen in the Pagano study, 11 the treatment progressed from topical therapy to yeast infection therapy (if indicated) that included ketoconazole or fluconazole, to amitriptyline, then to carbamazepine if amitriptyline failed. These results showed only 4 of the 30 (13%) patients treated with carbamazepine had a positive response to the anticonvulsant (ie, reduction of at least one grading of severity of painful intercourse).
Topical Therapies
When oral therapy is ineffective, intolerable, or undesirable, vaginal administration is an alternative route of delivery. For the purposes of this article, vaginal administration refers to applying the medication where the patient feels pain, whether that is a localized or generalized area of the vulva. This is most commonly accomplished by compounding the drug into an ointment or cream. The vaginal route provides targeted therapy with decreased systemic adverse effects while avoiding complications associated with oral dosing such as interpatient variability and first-pass metabolism. 22, 23 Disadvantages to vaginal topical therapy are personal hygiene, timing of application with sexual intercourse, and local irritation. 24 Another potential hindrance is dosage frequency, which can be as often as 7 times per day. Application frequencies for individual drugs can be seen in Table 3 .
When compounding medications for vaginal use, it is key to consider the anatomical features of the vagina. The compounded agents should be buffered to a pH of 4.5 to match the normal vaginal pH of 3 to 5.5 during childbearing years. 22 A hydrophilic base, such as petrolatum, should be used due to the vagina's mucosal membrane properties. Since indications are seldom included on compounded prescriptions, the pharmacist should ask the patient her intended use to make sure the correct base is chosen. 25 Last, care should be taken to ensure sterility of the final product. Table 3 provides a condensed view of the 12 studies discussing topical treatment options. Please note that a study by Foster et al 13 was also listed in Table 2 and was not repeated in Table 3 .
Oral antidepressants, specifically amitriptyline, continue to be widely used for the treatment of vulvodynia. However, there are limited studies utilizing this medication in a topical route. In one study when amitriptyline was administered in a cream, 56% of patients responded to therapy with 10% of those being completely pain free at the end of 3 months. This study also showed improvement in patients who had previously failed treatment with oral amitriptyline. The most common adverse effects were local skin irritation and burning. The authors suggested if a patient cannot tolerate a higher dose of systemic amitriptyline, a lower dose of oral therapy could be combined with topical amitriptyline cream. 26 In addition to being studied alone, amitriptyline has also been studied as a mixture with baclofen in a cream. According to Nyirjesy et al, 27 this combination cream significantly decreased the patients' social activity interference, difficulty lubricating, and overall intercourse pain level.
Since oral gabapentin is frequently used for neuropathic pain, Boardman et al 23 hypothesized that topical gabapentin could be effective in treating vulvodynia. Records were gathered of pre-and postmenopausal women diagnosed with localized or generalized vulvodynia over a 6-year period and were narrowed to those treated with topical gabapentin. Gabapentin cream was dispensed to patients in strengths of 2%, 4%, or 6% with the initial treatment strength chosen by the provider. Out of the 35 women available to evaluate, 80% saw at least a 50% reduction in pain scores with 29% having complete remission of pain. However, the authors did not control for concomitant use of other vulvodynia therapies during treatment and did not use consistent dosing practices in the strength of cream chosen for each patient. Therefore, it is difficult to assess the true magnitude of topical gabapentin's efficacy in vulvodynia. Adverse effects causing discontinuation of therapy included local irritation and urinary problems such as retention, frequency, and recurrent urinary tract infections.
Topical lidocaine has become a popular vulvodynia treatment due to vulvodynia's similarity to post-herpetic neuralgia. One randomized placebo-controlled study 13 was performed using topical lidocaine and demonstrated no efficacy over placebo. However, other trials have demonstrated increased quality of life. In a trial by Zolnoun et al, 28 76% of participants reported the ability to have intercourse after treatment compared with 36% beforehand. Another study included subjects using topical lidocaine that saw significant increases in sexual desire and satisfaction. 29 Despite disagreement in efficacy results between studies, if a patient finds relief with topical lidocaine, it can be applied in the 2% strength up to 6 times per day without concerns for toxicity. 29 It gives rapid relief with an onset of action in as little as 20 minutes. If being used to facilitate intercourse, patients should be counseled that residual product could transfer to their partner causing numbness, but a condom can help prevent this adverse effect. 5 A study was recently published showing early data of combination meloxicam 0.3% and lidocaine 5% gel used to treat vulvodynia. These drugs were used together locally in an attempt to decrease inflammation and nociceptive pain thresholds. Seventy-five percent of participants had a subjective improvement in their symptoms and reported a 1-to 4-point pain scale reduction. Adverse effects included burning and stinging. 30 Pelvic floor hypertonicity and vulvodynia are frequently present concomitantly. 31, 32 Baclofen's muscle relaxation actions and decreased adverse effect profile make it a feasible treatment option. 33, 34 One study found baclofen an effective treatment when combined in a cream with amitriptyline. 27 Additionally, a case report used a compounded baclofen cream with oral palmitoylethanolamide, which is a fatty acid produced naturally and taken orally as a food supplement to decrease inflammation. The patient's pain had decreased 30% after 1 month, and she had an increased quality of life after 3 months. 34 Although no research has been performed on baclofen as monotherapy, this could be a treatment option for patients with suspected pelvic floor hypertonicity.
Levels of gonadal hormones (ie, estrogen and testosterone) appear to play a role in pain transmission at various sites. Recently, topical creams containing gonadal hormones have been tested to target premenopausal vulvodynia along with the comorbidity of interstitial cystitis/bladder pain syndrome (IC/BPS). IC/BPS and vulvodynia both belong to a larger category of chronic pelvic pain syndromes, which may often overlap. A study of premenopausal patients using estriol cream saw significant improvement in both bladder and vaginal pain symptoms. 35 Since vulvodynia symptoms can be similar to those experienced during menopause, it has been hypothesized that vulvodynia could be caused by hypoestrogenism, even in premenopausal patients. 35 This hypoestrogenic state could come from continued use of combined hormonal contraceptives, which modify the vestibular tissue by decreasing endogenous estrogen synthesis and altering free levels of testosterone. 36, 37 This could also result in lower vestibular pain tolerances and thresholds when compared with controls. 38 In one study, after discontinuing the combined hormonal contraceptives and initiating treatment with topical estradiol and testosterone, vestibular pain scores were reduced. 36 Care should be used when treating premenopausal patients with topical hormones due to the risk of fetal malformations if pregnancy were to occur. 39 Regardless of the cause, hypoestrogenism appears to correlate with increased nerve fiber hypertrophy and thickening in primary vestibulodynia. 40 Although more research is needed, topical hormonal therapy seems effective and should be considered in patients with other comorbidities or etiologies that may be hormone related.
Injectable Therapies
Several injectable therapies exist for vulvodynia pain that is more localized in nature. Those showing efficacy include enoxaparin, botulinum toxin A, and corticosteroids. Although effective, injectable therapies are not often recommended due to their inconvenience and cost. In general, the frequency of injections, administration in a practitioner's office (botulinum toxin and corticosteroids), and specialized patient education (enoxaparin) may make this route of administration difficult for patients. 5, 41 It has been hypothesized that vulvodynia is caused by heparanase proteins weakening cellular membranes and allowing nerve fibers to penetrate through and proliferate. Therefore, enoxaparin, with its antiheparanase properties, has been studied to help alleviate vulvodynia pain. When administered subcutaneously at 40 mg once daily, enoxaparin was shown to decrease Q-tip touch test pain scores at the end of the 90-day trial and continued 3 months later. Bleeding risk is increased, and treatment duration is unclear for vulvodynia outside of a trial setting. 41 Due to its anticholinergic effects and subsequent reduction in muscle spasm frequency, botulinum toxin A has been shown to decrease and even cure vulvodynia pain in case studies. 5 However, the only randomized-controlled trial performed using botulinum toxin A in vulvodynia found no difference from placebo. 6 Although rare, botulinum toxin A carries a risk of systemic effects if it spreads beyond the site of injection.
Finally, locally injected triamcinolone, betamethasone, and methylprednisolone have been studied due to their antiinflammatory effects and in some cases have improved pain in as less as 1 to 2 weeks. 5 Due to the use of other medications in combination with the corticosteroids, it is difficult to assess their efficacy in these studies.
Nonpharmacologic Therapies
Many treatment modalities have been researched outside of traditional pharmacological strategies due to the multifactorial symptomatic nature of vulvodynia. More promising evidence supports a combination approach of pharmacological therapy, psychotherapy, and physiotherapy, reserving surgery as a last-line option.
Vulvodynia can affect a woman's relationships and quality of life, with depression being a common comorbidity. Antidepressants and psychotherapy used concomitantly can assist in reducing pain, fear, and anxiety. Behavioral modifications may also play a role in reestablishing satisfying sexual functioning. It should again be emphasized with the patient that this combination approach is to treat the pain, which is a real disease and not an imagined condition. 5 Physical therapy via the use of pelvic floor exercises has become a mainstay of therapy. One study compared pelvic floor muscles of patient groups with vulvar pain versus a control patient group with no vulvar pain. The study showed that the patients with provoked vulvodynia had the highest average muscle tension, followed by patients with generalized vulvodynia, then the no-pain control group. These results led researchers to believe that the chronic pelvic pain experienced in each group was due to varying levels of hypertonicity that could be treated with physical therapy. 42 The primary goal of physical therapy is to retrain the pelvic floor muscles in order to improve muscle floor strength and voluntary muscle relaxation, while also decreasing the fear of penetration. [43] [44] [45] Surgery, typically consisting of vulvar excision and vestibulectomy, has shown positive results; however, it should be reserved as last-line therapy due to successes of first-line therapy, risks of surgery, and the long recovery process. Success rates vary from 60% to 90%, depending partially on the surgeon's experience and technique. [46] [47] [48] A study attempting to assess the long-term success of surgery found that while 66.7% of women experienced improvement in pain associated with sexual intercourse, 78.1% receiving less invasive treatment also felt improvement of pain scores. 48 Other alternative therapies requiring more controlled studies include acupuncture, localized transcutaneous electrical nerve stimulation (TENS) therapy applied to the labia majora, and avoiding diets high in oxalates.
As an alternative to Western medicine techniques, patients may elect to try acupuncture. It is proposed that positioning acupuncture needles at specific pain points across the body can cause a natural release of endorphins and opioids, which may increase the flow of pain-killing chemicals to problematic areas. 49 There have been 3 studies testing its utility in treating vulvodynia, with each study including less than 40 patients. [50] [51] [52] One randomized-controlled study did show statistically significant pain score reductions for sensory pain (P = 0.01) and total pain (P = 0.02). However, this was a pilot study limited to a onetime acupuncture session. 50 The other 2 studies lasted for 5 to 10 weeks, but lacked a control and did not include specifics on how the pain was assessed. 51, 52 Due to the ongoing evidence of nerve involvement, researchers have explored the use of TENS therapy. One study showed statistically significant (P < 0.01) lowered pain scores when the TENS unit was placed on the labia majora. The recommended use of TENS was 3 times daily for a total duration of 90 minutes. 53 It has been hypothesized that certain foods result in high concentrations of oxalates in the urine, which may exacerbate pain associated with vulvodynia. However, it has not been proven to be a direct cause. Rhubarb, nuts, spinach, celery, beets, chocolate, tea, wheat bran, and strawberries have been shown to increase urinary oxalate excretion. 54, 55 Due to its ability to bind oxalates, calcium citrate containing 200 mg of calcium and 950 mg of citrate taken 2 tablets 3 times daily was used in a case study to limit urinary oxalates. 55 While the case study showed positive results for this patient, other studies have not shown a direct correlation between vulvodynia and urinary oxalate levels. Limiting these foods and using calcium citrate as an oxalate binder may be advantageous for patients continuing to struggle with pain control despite trying multiple other modes of therapy.
56
Ineffective and/or Inconvenient Therapies
Nitroglycerin cream and capsaicin cream have shown some efficacy when treating vulvodynia. However, they are not frequently used due to the adverse effects experienced exceeding the possible benefits.
In a pilot study using 0.2% nitroglycerin cream, the authors hypothesized that the metabolite nitric oxide would relax smooth muscle and inhibit inflammatory cascades. However, the adverse effect of headache was prevalent 57 and limits nitroglycerin's use as a viable treatment option.
Capsaicin has additionally been studied due to its actions on substance P, which causes a burning-like sensation. 58 In 2 studies, capsaicin's use was limited due to a cumbersome application process, which included pretreatment with lidocaine and in some cases ice packs as numbing agents. 59, 60 In patients with positive responses, discontinuation of therapy caused symptoms to return in an average of 15 days. Reinstitution of a twice-weekly application regimen resulted in symptoms fading in an additional 20 days. 60 This lack of long-term effectiveness limits treatment of a chronic pain condition. This evidence shows that even though some positive responses have been seen, this therapy should be considered as a last-line option when no other treatment modalities have worked.
Other agents that have been studied are topical nifedipine, topical cromolyn sodium, topical corticosteroids, oral narcotics, and other oral analgesics such as nonsteroidal anti-inflammatory drugs and acetaminophen. However, studies have shown they lack efficacy in vulvodynia and therefore are not used in therapy. 61, 62 Additionally, an injectable therapy that has been studied is interferon-α. 46 Studies have found it to be ineffective and not tolerated due to its adverse effects of flu-like symptoms and malaise. 5 
Final Considerations
There are several patient-specific factors that should be considered when selecting therapy. As mentioned previously, 8 patients prefer oral therapy to topical therapy due to comfort and convenience. However, topical administration may be desired due to targeted therapy and decreased risk of adverse effects. Since this disease affects women of childbearing age, pregnancy risk of medications should also be considered, especially with use of topical gonadal hormones. Adverse effects of medications, the patient's symptoms on presentation, and comorbidities all need to be considered when selecting initial therapy. Although oral TCAs are the most studied, other therapies that have less research may also be considered as first line. Therefore, it is difficult to make any step-wise recommendations for clinicians.
Conclusion
Vulvodynia is a multifactorial disorder with no one proven etiology; therefore, several therapies exist for treatment. Although some prospective studies have shown trends toward efficacy, there are noted limitations, including lack of consistent randomization and placebo controls, as well as small sample sizes. Treatment should be individualized to patients' needs and typically includes elements of psychotherapy, physical therapy, and pharmacological therapy. Both oral and topical medications can be considered and should be optimized based on the patients' symptoms and adverse effects. Patients should expect to take several months to achieve maximal symptom reduction due to dose titrations and potential changes in medication therapy. Additional research is needed to increase knowledge and further develop vulvodynia treatments.
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